One Foundation for the Whole Vaccine Process

Where the cost and the risk sit in a vaccine programme

Of all the modalities in this series, vaccines have the widest process span. A vaccine programme begins where a cell-therapy or antibody programme does - a substrate cell line that has to be grown, often to very large scale - and ends where an mRNA programme does - a formulated, filled injectable. Between those two points sit two quite different disciplines: the biology of growing virus or antigen in a cell substrate, and the chemistry of clarifying, clearing, purifying and formulating what comes out. Most suppliers are strong at one end or the other. The programme's cost, its timeline and much of its risk sit in stitching the two halves together from a fragmented supplier base - and in doing it fast, because vaccines are the one modality routinely built against an emerging-pathogen clock.

The upstream carries a particular dependency. A viral vaccine is only as good as the cell substrate and the medium that grows it: Vero, MDCK, BHK21, insect cells and others each need media tuned to the line, and switching medium mid-programme can change yield, glycosylation and the downstream clearance burden. The downstream carries a particular obligation: because the product is grown in cells, residual host-cell DNA and host-cell protein are regulated impurities with hard release limits, so nuclease treatment and purification are not polish steps but compliance steps. Sourcing the media, buffers, nuclease reagents and excipients that run all of this from many vendors is exactly what slows qualification and scale-up on a modality whose point is often to be ready first.

A vaccine starts as biology in a cell and ends as chemistry in a vial. The supplier who makes both the culture medium and the formulation buffer can carry the whole span - and carry it fast.

One shared upstream, then a modality-specific downstream

Every vaccine starts the same way - expand a substrate cell line, then infect or transfect it - and PAN covers that shared upstream almost end to end, including the cell-line-specific viral culture media that define the platform. The downstream then branches by modality, but the buffer, nuclease and stabiliser chemistry is largely shared, so a small set of qualified stocks recurs across the whole process.

Which downstream steps apply depends on the modality: enveloped live/inactivated viral vaccines are harvested, clarified, nuclease-treated and purified; non-enveloped or vector vaccines add a lysis step; recombinant subunit vaccines follow a capture-and-polish route. The shared buffer and stabiliser stocks recur across all of them.

One foundation - a handful of stocks, reused across the process

Look across the steps and the same pattern appears as in every PAN process edition: the dozens of working media and buffers are built from a small set of concentrated stock solutions that recur again and again. WFI-quality water is the base of every step. DPBS runs through cell handling, infection and harvest; Tris 1 M, NaCl 5 M and phosphate recur across nuclease treatment, purification, exchange and formulation; the magnesium cofactor serves the nuclease step; and the formulation excipients - sucrose, trehalose, mannitol, glycerol, polysorbate 20/80, rHSA - carry from stabilisation into the final injectable. Qualify a handful of stocks once, and they serve the whole process - fewer SKUs to qualify, one consistent chemistry from research to GMP.

Delivered as process bundles - one box per step

PAN delivers the range the way the process runs it - as step-specific process bundles, one box per step, each holding the exact set of media and liquids that step needs, every bottle labelled with its name, article number, lot, volume, storage and production date. A team orders the bundle for its step - the Cell Expansion Bundle, the Nuclease Treatment Bundle, the Purification Bundle, the Formulation Bundle - rather than assembling a catalogue list and reconciling it on receipt. The stocks are research grade today, GMP on request, and the downstream buffers can be produced on the WFI Beyond water base as an added safety standard (Section 7). Full component-and-article-number listings are in Appendix A.

The substrate and the culture - where vaccine expertise lives

The upstream is where a vaccine programme is won or lost, and it is where PAN's deepest expertise sits. This is no recent extension: PAN-Biotech has spent 38 years on the cell-culture upstream - the media, sera and supplements that keep cells productive and consistent - with a catalogue of around 1,800 products built over that time, and it is the house that developed Panexin, described as the world's first serum-replacement product. The cell-line-specific viral culture media sit squarely on that heritage. Cell line development & maintenance (V1) establishes and banks the substrate - master and working cell banks, cryopreserved in chemically defined, protein-free or DMSO-free freezing media, with antibiotics and glutamine for maintenance, all on a WFI-quality water base. Cell expansion (V2) is the heart of it: PAN makes cell-line-specific viral culture media for the substrates the industry actually uses - Panserin ProVero for Vero (polio, rabies, influenza), a serum-free medium for MDCK (influenza), EMEM Fibroblast and Panserin 401 for BHK21, Spodopan for Sf9/Sf21 insect cells (baculovirus, subunit and VLP) and Schneider's Drosophila Medium for S2 - with the base media, supplements, dissociation reagents and shear protectant that round out a bioreactor process.

Virus infection / transfection (V3) then starts production: the substrate is infected with seed virus, or transfected for virus rescue, viral-vector vaccines and recombinant-antigen expression, on WFI-quality water and DPBS. Running this on serum-free and protein-free media is not just a safety-and-supply choice; it lowers lot-to-lot variability and cuts the downstream clearance burden - fewer undefined proteins to remove later. Because the identical media are available GMP on request with no reformulation, the substrate a programme develops on is the substrate it manufactures on.

Harvest, host-cell DNA clearance, purification and formulation

The downstream turns a cell culture into a purified, formulated injectable. Viral harvesting & clarification (V4) recovers the virus or antigen on WFI-quality water and DPBS wash buffers; for non-enveloped or lysis-based products, cell lysis (V5) releases the intracellular product with PANclear APG, SDS and EDTA. Nuclease treatment (V6) is the step a cell-derived vaccine cannot skip: a broad-range endonuclease and DNase I, with a magnesium cofactor, digest host-cell DNA and RNA down to the regulated residual limit - a release attribute for any cell-substrate vaccine, not an optional polish.

Purification / chromatography (V7) captures and polishes the product on ion-exchange, density-gradient and buffer stocks (NaCl 5 M, Tris, phosphate, sodium acetate, NaOH, sucrose), and concentration / buffer exchange (V8) concentrates and diafilters into the formulation buffer by tangential-flow filtration. Formulation (V9) is the excipient-grade set that turns bulk into an injectable - tonicity (NaCl, sodium chloride 0.9 %), stabilisers and cryoprotectants (sucrose, trehalose, mannitol, glycerol), surfactants (polysorbate 20 and 80) and an animal-free stabiliser (rHSA) - with the final formulation built on WFI Beyond. One qualified set of stocks carries the whole downstream, and every buffer in it can be built on WFI Beyond. (Adjuvants and preservatives are specialised formulation actives outside the PAN range and are sourced separately.)

Water, and why it sets the floor for an injectable

Water is the base of every medium, every buffer and the final formulation, so it sets the quality ceiling for the whole process. For a vaccine the decisive moment is the end: the product is an injectable, and the water in the final formulation goes into a human being. The pharmacopoeial Water for Injection monograph (Ph. Eur. 0169, its core dating to 1969) sets the floor; WFI Beyond starts where the monograph stops.

What WFI Beyond is. WFI Beyond is PAN's beyond-compendial Water for Injection - water that first meets the monograph and then goes past it, proven lot by lot on the Certificate of Analysis:

• Endotoxin more than 50x below the compendial limit (spec < 0.005 EU/mL) - the attribute that matters most for an injectable, because endotoxin in a final vaccine formulation cannot be removed downstream and drives the product's pyrogen risk.
• Sterile (0.1 µm filtered, filled into gamma-irradiated single-use containers) and animal-component-free, with a signed BSE/TSE and ICH Q3 declaration - a clean fit for a sterile injectable on a serum-free process.
• Nuclease-free - RNase and DNase not detected - useful wherever a vaccine route handles nucleic-acid-sensitive intermediates or a nucleic-acid-based product.
• All 24 ICH Q3D elemental impurities specified and measured by ICP-MS on every lot - a first for a water - so the elemental-impurity question is answered at the water layer rather than argued downstream.
• DMF-backed - a filed FDA Type IV (excipient) Drug Master File (MF044505), referenceable in an IND/BLA through a Letter of Authorization.

(The full water story is In-Depth · Industry Edition D02 · Water: The WFI Beyond Standard.)

Built on WFI Beyond  the mark for the water beneath a molecule that earns it.

The DMF advantage

Two of the universal utilities are backed by filed FDA Type IV Drug Master Files - DPBS (MF044371) and WFI Beyond (MF044505). Type IV is the FDA's category for excipients, which is what these materials are in a finished vaccine, so you reference them in your IND/BLA through a Letter of Authorization rather than re-proving or reconstructing them - taking months of independent testing off the critical path, with PAN's proprietary detail protected in the FDA's confidential file. And PAN goes one step further: on a customer's request, PAN-Celltech will file the products they rely on with the FDA as well, extending the same regulatory shortcut to the materials that matter most to their programme. (DMF and stability support are optional, on-request services.)

The proof - rapid GMP supply at scale

Vaccines are the modality where speed is most often the point, and PAN's record is built on exactly that. The GMP liquids are made by the PAN-Celltech GMP operation that has proven itself at commercial scale - GMP-compliant and audit-proven manufacture in an EU Annex 1 facility (a capability, not a certification):

Track-record figures are anonymised; capacity figures are stated as "up to". Read the anonymised vaccine-supply story - ~50,000 L of GMP supply in under five weeks - in the Knowledge Hub.

The story above is shared. The sections below translate it into the terms of a specific role - read yours, skip the rest.